Is NCT04067336 recruiting?

Yes, NCT04067336 is currently recruiting. This acute myeloid leukemia study is enrolling participants at 23 locations.

What is the status of NCT04067336?

NCT04067336 is currently recruiting. This is a Clinical Trial trial for acute myeloid leukemia sponsored by Kura Oncology, Inc.. Status verified Nov 10, 2025 via ClinicalTrials.gov.

Where is NCT04067336 enrolling participants?

NCT04067336 has 23 active sites including Gilbert, Arizona; Phoenix, Arizona; Los Angeles, California and 20 more locations.

Who is eligible for NCT04067336?

This acute myeloid leukemia trial is targeting 263 participants. Detailed eligibility criteria including age requirements and medical history are listed on this page.

Who can participate in this Acute Myeloid Leukemia study?

Eligibility varies by study, but generally includes adults diagnosed with Acute Myeloid Leukemia who meet specific medical criteria. Complete the interest form above to learn if you may qualify.

Is the study available in Gilbert, Arizona?

Yes! This study has active research sites in Gilbert, Phoenix, Los Angeles. When you express interest, you'll be connected with the site nearest to you.

What are the benefits of joining a clinical trial for Acute Myeloid Leukemia?

Participants often receive: access to new treatments before they're widely available, close monitoring by medical professionals, study-related care at no cost, and the opportunity to contribute to medical research.

⚡Your ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT04067336 RECRUITINGIRB Ready

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Express Your Interest Today

Interested in learning more? Complete the form below.

First Name *

Last Name *

Email Address *

Phone Number *

ZIP Code *

Age Range *

Preferred Location

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

No-Cost Study Care
Advance Medical Science
Contribute to groundbreaking research
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel (varies by study)
Help Others
Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

1Submit this form
2Phone screening
3In-person assessment if eligible
4Begin participation

About This Study

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.

Who Can Participate

Inclusion Criteria

Patients with refractory or relapsed AML defined as the reappearance of ≥ 5% blasts in the bone marrow and who have also failed or are ineligible for any approved standard of care therapies, including HSCT. 1. Phase 1b:

Patients with a documented lysine\[K\]-specific methyltransferase 2-rearrangement (KMT2A-r), or

Patients with a documented nucleophosmin 1 mutation (NPM1-m) 2. Phase 2:

Patients with a documented nucleophosmin 1 mutation (NPM1-m) 3. Sub-studies:

Sub-studies 1 and 2: Patients with R/R AML with NPM1-m or other mutations associated with MEIS1 overexpression.

Sub-study 3: Patients with R/R Acute Lymphoblastic Leukemia (ALL) with KMT2A-r.

Sub-study 4: Patients with R/R AML with mutations associated with MEIS1 overexpression. 4. ≥ 18 years of age. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and a life expectancy of at least 2 months. 6. Adequate liver and kidney function according to pro

❓ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

📋

Study Type

INTERVENTIONAL

👥

Target Enrollment

263 participants

⚧

Gender

ALL

🏢

Sponsor

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

🔒 Secure · 🏥 Expert Care

Find More Leukemia Trials by City

Browse all leukemia clinical trials in these cities — not just this study.

Gilbert, Arizona Phoenix, Arizona Los Angeles, California Jacksonville, Florida Chicago, Illinois Indianapolis, Indiana

Browse More Trials by Condition

Leukemia Trials Acute Myeloid Leukemia Trials Heart Attack Trials Myocardial Infarction Trials Osteogenesis Imperfecta Trials All Conditions →

Looking for Acute Myeloid Leukemia Treatment in Gilbert?

Join others in Arizona exploring innovative treatment options through clinical research

Acute Myeloid Leukemia Treatment Options in Gilbert, Arizona

If you're searching for Acute Myeloid Leukemia treatment in Gilbert, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Gilbert, Phoenix, Los Angeles and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Acute Myeloid Leukemia. All study-related care is provided at no cost to participants.

Local Sites

3 locations in Arizona

Now Enrolling

Up to 263 participants

Quick Start

Screening available now

Why Consider a Clinical Trial for Acute Myeloid Leukemia?

Potential Benefits

✓Access to new treatment approaches before public availability
✓Close monitoring by experienced medical professionals
✓Study-related care provided at no cost
✓Contribute to medical research for Acute Myeloid Leukemia

What to Expect

→Initial screening to determine eligibility
→Regular check-ups and monitoring visits
→Possible compensation for time and travel
→You can withdraw at any time

Frequently Asked Questions About This Acute Myeloid Leukemia Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT04067336. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.